250 related articles for article (PubMed ID: 30633369)
1. Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics.
Mohamed MF; Trueman S; Feng T; Anderson J; Marbury TC; Othman AA
J Clin Pharmacol; 2019 Jun; 59(6):856-862. PubMed ID: 30633369
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I-III Clinical Trials.
Klünder B; Mittapalli RK; Mohamed MF; Friedel A; Noertersheuser P; Othman AA
Clin Pharmacokinet; 2019 Aug; 58(8):1045-1058. PubMed ID: 30945116
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials.
Nader A; Stodtmann S; Friedel A; Mohamed MF; Othman AA
J Clin Pharmacol; 2020 Apr; 60(4):528-539. PubMed ID: 31701537
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics.
Trueman S; Mohamed MF; Feng T; Lacerda AP; Marbury T; Othman AA
J Clin Pharmacol; 2019 Sep; 59(9):1188-1194. PubMed ID: 30973649
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials.
Klünder B; Mohamed MF; Othman AA
Clin Pharmacokinet; 2018 Aug; 57(8):977-988. PubMed ID: 29076110
[TBL] [Abstract][Full Text] [Related]
6. Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib.
Mohamed MF; Jungerwirth S; Asatryan A; Jiang P; Othman AA
Br J Clin Pharmacol; 2017 Oct; 83(10):2242-2248. PubMed ID: 28503781
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the Effect of Upadacitinib on the Pharmacokinetics of Bupropion, a Sensitive Cytochrome P450 2B6 Probe Substrate.
Mohamed MF; Minocha M; Trueman S; Feng T; Enejosa J; Fisniku O; Othman AA
Clin Pharmacol Drug Dev; 2021 Mar; 10(3):299-306. PubMed ID: 32648334
[TBL] [Abstract][Full Text] [Related]
8. Exposure-Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection.
Mohamed MF; Klünder B; Camp HS; Othman AA
Clin Pharmacol Ther; 2019 Dec; 106(6):1319-1327. PubMed ID: 31194885
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis.
Mohamed MF; Camp HS; Jiang P; Padley RJ; Asatryan A; Othman AA
Clin Pharmacokinet; 2016 Dec; 55(12):1547-1558. PubMed ID: 27272171
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended-Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials.
Mohamed MF; Zeng J; Marroum PJ; Song IH; Othman AA
Clin Pharmacol Drug Dev; 2019 Feb; 8(2):208-216. PubMed ID: 29688617
[TBL] [Abstract][Full Text] [Related]
11. Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment.
Veeravalli V; Dash RP; Thomas JA; Babu RJ; Madgula LMV; Srinivas NR
Drug Saf; 2020 Aug; 43(8):711-725. PubMed ID: 32367507
[TBL] [Abstract][Full Text] [Related]
12. Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure-Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib.
Mohamed MF; Beck D; Camp HS; Othman AA
J Clin Pharmacol; 2020 Feb; 60(2):188-197. PubMed ID: 31448433
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis.
Sandborn WJ; Ghosh S; Panes J; Schreiber S; D'Haens G; Tanida S; Siffledeen J; Enejosa J; Zhou W; Othman AA; Huang B; Higgins PDR
Gastroenterology; 2020 Jun; 158(8):2139-2149.e14. PubMed ID: 32092309
[TBL] [Abstract][Full Text] [Related]
14. The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects.
Mohamed MF; Trueman S; Feng T; Friedman A; Othman AA
J Clin Pharmacol; 2019 Apr; 59(4):510-516. PubMed ID: 30500075
[TBL] [Abstract][Full Text] [Related]
15. Upadacitinib pharmacokinetics and exposure-response analyses of efficacy and safety in psoriatic arthritis patients - Analyses of phase III clinical trials.
Muensterman E; Engelhardt B; Gopalakrishnan S; Anderson JK; Mohamed MF
Clin Transl Sci; 2022 Jan; 15(1):267-278. PubMed ID: 34464029
[TBL] [Abstract][Full Text] [Related]
16. Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS.
Martens-Lobenhoffer J; Tomaras S; Feist E; Bode-Böger SM
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Jan; 1188():123076. PubMed ID: 34871917
[TBL] [Abstract][Full Text] [Related]
17. Upadacitinib for the treatment of rheumatoid arthritis.
Serhal L; Edwards CJ
Expert Rev Clin Immunol; 2019 Jan; 15(1):13-25. PubMed ID: 30394138
[No Abstract] [Full Text] [Related]
18. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.
Fleischmann R; Pangan AL; Song IH; Mysler E; Bessette L; Peterfy C; Durez P; Ostor AJ; Li Y; Zhou Y; Othman AA; Genovese MC
Arthritis Rheumatol; 2019 Nov; 71(11):1788-1800. PubMed ID: 31287230
[TBL] [Abstract][Full Text] [Related]
19. Exposure-Response Analyses for Upadacitinib Efficacy and Safety in the Crohn's Disease CELEST Study and Bridging to the Extended-Release Formulation.
Mohamed MF; Klünder B; Lacerda AP; Othman AA
Clin Pharmacol Ther; 2020 Mar; 107(3):639-649. PubMed ID: 31594037
[TBL] [Abstract][Full Text] [Related]
20. Clinical Pharmacokinetics of Upadacitinib: Review of Data Relevant to the Rheumatoid Arthritis Indication.
Mohamed MF; Klünder B; Othman AA
Clin Pharmacokinet; 2020 May; 59(5):531-544. PubMed ID: 31867699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
